Crinecerfont in Adult Congenital Adrenal Hyperplasia

IF 96.2 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

New England Journal of Medicine Pub Date : 2024-10-24 DOI:10.1056/nejmc2411263

引用次数: 0

Abstract

To the Editor: In the phase 3 CAHtalyst trial reported by Auchus et al. (Aug. 8 issue),1 the use of crinecerfont allowed for a greater reduction in the mean daily glucocorticoid dose than placebo (...

查看原文本刊更多论文

成人先天性肾上腺皮质增生症中的克林塞丰

致编辑：在Auchus等人报道的CAHtalyst 3期试验（8月8日刊）1中，与安慰剂相比，使用crinecerfont可使糖皮质激素的平均日剂量减少更多（...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

New England Journal of Medicine 医学-医学：内科

CiteScore

145.40

自引率

0.60%

发文量

1839

审稿时长

1 months

期刊介绍： The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.